Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Primary congenital glaucoma (PCG) is characterized by elevated intraocular pressure (IOP), enlargement of the globe (buphthalmos), edema, and opacification of the cornea with rupture of Descemet's membrane (Haab's striae), thinning of the anterior sclera and iris atrophy, anomalously deep anterior chamber, and structurally normal posterior segment except for progressive glaucomatous optic atrophy. Symptoms include photophobia, blepharospasm, and excessive tearing. Typically, the diagnosis is made in the first year of life. Depending on when treatment is instituted, visual acuity may be reduced and/or visual fields may be restricted. In untreated individuals, blindness invariably occurs.
Biomarker and diagnostic research for primary congenital glaucoma has been reported in the published literature.
2 clinical trials registered. Interventions under study include other interventions and medical devices. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
147 publications have been identified in PubMed for primary congenital glaucoma. Research spans Clinical Trial Publication (23%), Epidemiology / Natural History (18%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 31 |
Data assembled from 3 of 12 sources · Last updated Sep 17, 2026, 7:16 PM UTC
Disease patterns and progression | 24 | 18% |
Patient case studies | 22 | 17% |
Research summaries | 21 | 16% |
Laboratory research | 17 | 13% |
New treatment approaches | 10 | 8% |
Testing and diagnosis research | 5 | 4% |
Other research | 2 | 2% |
Pathak AK (2026). [PMID: 41739128](https://pubmed.ncbi.nlm.nih.gov/41739128/). *Indian J Ophthalmol*. [Clinical Trial Publication]
Abbas J (2026). [PMID: 41875194](https://pubmed.ncbi.nlm.nih.gov/41875194/). *J Glaucoma*. [Review / Meta-Analysis]
García-Bermúdez M (2026). [PMID: 41990436](https://pubmed.ncbi.nlm.nih.gov/41990436/). *J Fr Ophtalmol*. [Other]
Elwehidy AS (2026). [PMID: 42092636](https://pubmed.ncbi.nlm.nih.gov/42092636/). *Ophthalmol Glaucoma*. [Clinical Trial Publication]
Hirano S (2026). [PMID: 42131671](https://pubmed.ncbi.nlm.nih.gov/42131671/). *Cureus*. [Case Report / Case Series]
Sun Y (2026). [PMID: 42285468](https://pubmed.ncbi.nlm.nih.gov/42285468/). *Am J Ophthalmol*. [Gene Therapy / Novel Therapeutics]
Jiang J (2026). [PMID: 41460872](https://pubmed.ncbi.nlm.nih.gov/41460872/). *Eye Contact Lens*. [Clinical Trial Publication]
Matsuo T (2026). [PMID: 41970067](https://pubmed.ncbi.nlm.nih.gov/41970067/). *Cureus*. [Case Report / Case Series]
Bayoumi NHL (2026). [PMID: 40736058](https://pubmed.ncbi.nlm.nih.gov/40736058/). *J Pediatr Ophthalmol Strabismus*. [Clinical Trial Publication]
Saha BC (2026). [PMID: 41936534](https://pubmed.ncbi.nlm.nih.gov/41936534/). *Eur J Ophthalmol*. [Review / Meta-Analysis]